Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo

NCT00099970 is registered in ClinicalTrials.gov with PDL BioPharma, Inc. as lead sponsor.

NCT NCT00099970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00099970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo
Lead sponsor
PDL BioPharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2004
Completion date
March 31, 2006
Enrollment
40
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, metastases